Article Text

Download PDFPDF

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
  1. K Lykopoulos1,
  2. P Collins2,
  3. M Hall2,
  4. R Ehness3,
  5. J Barth3 and
  6. J Louahed2
  1. Aff1 grid.418236.a0000000121620389GSK London UK
  2. Aff2 GSK Vaccines Rixensart Belgium
  3. Aff3 grid.420105.20000 0004 0609 8483GSK Munich Germany

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Precision medicine with modern immunotherapeutics often requires pre-therapeutic access to novel and sometimes complex diagnostic tests. Test development and access to tests including reimbursement often lacks behind medicine development and availability of medicines, potentially creating a gap for physicians to administer and patients to receive an optimised treatment regime. Pharmaceutical companies are challenged by the fact of having to co-develop a diagnostic method, a process which many of them are not accustomed to. In addition, many healthcare systems have no way of allowing in parallel evaluation of diagnostic test and medicine with a view to reimbursement.

This presentation illustrates approaches using the developmental history of the MAGE-A3 cancer immunotherapeutic to both address the developmental hurdle through innovative models and partnerships, as well as the market access hurdle through appropriate market understanding and evidence generation.

Insights and solutions of pre-clinical, clinical and market research/insight will be presented.